Anna D. Garrett, PharmD, BCPS
Anna D. Garrett is a clinical pharmacist and president of Dr. Anna Garrett (www.drannagarrett.com). Her mission is to help women in midlife maximize their mojo! Contact her at [email protected]
AHA and ASA issue guidelines for stroke prevention in women
Conditions targeted by the first guidelines geared specifically to women include migraine, high blood pressure, preeclampsia, and atrial fibrillation.
PCC for warfarin reversal does not reduce mortality compared to FFP
Compared to plasma, treatment with 4-factor PCC for warfarin reversal in patients with intracerebral hemorrhage does not seem to reduce 30-day all-cause mortality.
Renal dysfunction ups stroke risk in AF
Among more than 4,500 patients studied, there were 45 strokes and 103 major bleeding events after an average follow-up of 325 ± 164 days.
Factor Xa reversal agent designated breakthrough therapy
Portola is pursuing accelerated approval for andexanet alfa and plans to initiate studies on a larger scale in 2014.
Dabigatran vs. warfarin in patients with mechanical heart valves
The development of target-specific anticoagulants has raised the question of their possible use in patients with mechanical heart valves.
Bariatric surgery affects postoperative warfarin dosing
A small study of patients undergoing bariatric surgery suggests that weekly warfarin doses can change by as much as 20% postoperatively.
Many patients with AF lack indication for aspirin use
ORBIT-AF study results indicate that the benefit of adding aspirin therapy to oral anticoagulation for atrial fibrillation patients is unclear.
Aspirin not needed with anticoagulation/clopidogrel after MI, PCI in AF
A 12,000-patient Danish study suggests that the addition of one antiplatelet agent to oral anticoagulation is sufficient.
New prothrombin complex concentrate approved for acute bleeding
The FDA has approved a new plasma-derived product for the urgent reversal of vitamin-K antagonist (VKA) anticoagulation in adults with acute major bleeding.
Dabigatran bleeding events subject of new published data
Two new analyses result in conflicting findings

Poll